# US 2013/0280750 A1 · Maintenance of differentiated cells with laminins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0280750 A1
- Document ID: US20130280750A1
- Status: Published application
- Kind: A1
- Application number: 13/866,177
- Filed: 2013-04-19
- Published: 2013-10-24
- Earliest claimed: 2012-04-20
- Assignees: Biolamina AB
- Inventors: Karl Tryggvason; Karl Kristian Tryggvason; Anna Domogatskaya
- Web page: https://patentgrep.com/patent/US20130280750A1

## CPC

- C12N 5/0068: {General culture methods using substrates (for specific animal cell type C12N5/06)}
- C12N 5/0676: {Pancreatic cells}
- C12N 2501/998: Proteins not provided for elsewhere
- C12N 2533/52: Fibronectin; Laminin
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure describes methods of maintaining the phenotype of differentiated cells. Generally, the natural environment of the body is replicated for the differentiated cell. The differentiated cell is plated on a cell culture substrate comprising a laminin, such as laminin-521 or laminin-511. The substrate may also contain a cadherin. This maintains the phenotype of the differentiated cell.

## Claims

### Claim 1

A method for maintaining the phenotype of a differentiated cell, comprising:
plating the differentiated cell on a cell culture substrate comprising a laminin, wherein the laminin is an intact protein or a protein fragment.

### Claim 2 (depends on 1)

The method of claim 1, wherein the differentiated cell is an endothelial cell, a cardiomyocyte, a dopamine producing cell, a hepatocyte, a pancreatic islet, or a pancreatic beta cell.

### Claim 3 (depends on 1)

The method of claim 1, wherein the laminin is laminin-521 or laminin-511.

### Claim 4 (depends on 1)

The method of claim 1, wherein the laminin is an effective recombinant laminin.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cell culture substrate further comprises a cadherin.

### Claim 6 (depends on 5)

The method of claim 5, wherein the cadherin is e-cadherin.

### Claim 7 (depends on 5)

The method of claim 5, wherein the weight ratio of the laminin to the cadherin is from about 5:1 to about 15:1.

### Claim 8 (depends on 5)

The method of claim 5, wherein the weight ratio of the laminin to the cadherin is from about 5:1 to about 10:1.

### Claim 9 (depends on 5)

The method of claim 5, wherein the laminin is laminin-521 and the cadherin is e-cadherin.

### Claim 10 (depends on 5)

The method of claim 5, wherein the cell culture substrate consists of the laminin and the cadherin.

### Claim 11 (depends on 1)

The method of claim 1, wherein the cell culture substrate does not contain any differentiation inhibitors, feeder cells, differentiation inductors, or apoptosis inhibitors.

### Claim 12 (depends on 1)

The method of claim 1, further including applying a cell culture medium to the first stem cell.

### Claim 13 (depends on 12)

The method of claim 12, wherein the cell culture medium has an albumin concentration of at least 0.3 mM.

### Claim 14

A cell-based assay system, comprising:
a substrate comprising a laminin, wherein the laminin is an intact protein or a protein fragment; and
differentiated cells plated upon the substrate.

### Claim 15

A method of improving the transfection efficiency of differentiated cells, comprising:
plating differentiated cells on a substrate containing a laminin, wherein the laminin is an intact protein or a protein fragment;
transfecting the differentiated cells with a vector; and
culturing the transfected cells.

### Claim 16 (depends on 15)

The method of claim 15, wherein the laminin is laminin-521 or laminin-511.

### Claim 17 (depends on 15)

The method of claim 15, wherein the substrate further comprises a cadherin.

### Claim 18 (depends on 17)

The method of claim 17, wherein the cadherin is e-cadherin.

### Claim 19 (depends on 17)

The method of claim 17, wherein the weight ratio of the laminin to the cadherin is from about 5:1 to about 15:1.

### Claim 20 (depends on 15)

The method of claim 15, wherein the differentiated cells are transfected using a baculovirus, a lentivirus, lipofectamine, the calcium phosphate method, liposomes, cationic polymers, electroporation, sonoporation, optical transfection, gene electrotransfer, impalefection, hydrodynamic injection, gene gun, magnetofection, and viral transduction.
